How do ABBV and LLY differ fundamentally?

AbbVie focuses on immunology (autoimmune diseases via Skyrizi/Rinvoq) and aesthetics (Botox via Allergan) — established high-revenue products with high dividends and slower growth. Eli Lilly is transforming around GLP-1 metabolic drugs (tirzepatide for obesity and diabetes) — the fastest-growing product category in pharmaceutical history driving Lilly's exceptional revenue growth at minimal dividend.

What metrics matter most when comparing ABBV and LLY?

For AbbVie, track combined Skyrizi and Rinvoq quarterly revenue growth vs Humira erosion rate, and dividend payout ratio sustainability. For Eli Lilly, track Mounjaro and Zepbound combined quarterly revenue, tirzepatide manufacturing capacity availability, and GLP-1 market share versus Novo Nordisk's semaglutide.

Which is better for long-term investors — ABBV or LLY?

Both are compelling long-term pharma holdings for different objectives. AbbVie's dividend compounding through pharma cycles makes it one of the best income investments in healthcare. Eli Lilly's tirzepatide positions it to capture the obesity market through the next decade, potentially becoming the most valuable pharmaceutical company as obesity treatment becomes mainstream. Growth investors favor Lilly; income investors favor AbbVie.

Data as of: June 15, 2026

brimindinvest.com / compare / abbvie-vs-llyLIVE

ABBV

AbbVie Inc. · Healthcare

N/A

N/A this month

VERSUS

COMPARE

LLY

Eli Lilly and Company · Healthcare

N/A

N/A this month

Comparison scoreboard

MIXED SETUP

AI Scorei

ABBV N/A

LLY N/A

1Y Returni

ABBV N/A

LLY N/A

Fwd P/Ei

ABBV N/A

LLY N/A

Target Up.i

ABBV N/A

LLY N/A

Op. Margini

ABBV N/A

LLY N/A

Quick take

ABBV vs LLY Stock Comparison: AI Score, Valuation, Performance and Upside

ShareX LinkedIn Reddit Facebook WhatsApp

AbbVie and Eli Lilly are both large pharmaceutical companies with strong drug franchises, but with opposite investment profiles. AbbVie is the income-focused pharma dividend aristocrat managing the Humira transition to Skyrizi and Rinvoq — slower growth, reliable dividends. Eli Lilly is the highest-growth large pharma in decades, powered by tirzepatide's GLP-1 obesity dominance — minimal dividend, maximum growth multiple. They serve different investor needs.

ABBV vs LLY is the premier pharma dividend aristocrat managing Humira's biosimilar erosion with Skyrizi/Rinvoq as succession drugs and Botox aesthetics adding consumer healthcare (AbbVie) versus the highest-growth large pharma in history with tirzepatide GLP-1 treating obesity as the largest drug market ever created (Eli Lilly) — income compounding through immunology franchise vs GLP-1 blockbuster growth multiple.

Want a full valuation workup? 46-section report — AI Score, Monte Carlo forecast, bull/bear case, DCF, and more.

LLY Report

Normalized 1Y performance

ABBV

LLY

Not enough data to chart yet.

Recent returns

ABBV

LLY

Not enough data to chart yet.

Analyst price targets & sentiment

Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.

ABBV

Price target data unavailable

N/A

LLY

Price target data unavailable

N/A

Who should consider this stock?

ABBV may suit investors who:

prefer the premier pharma dividend aristocrat with 50+ consecutive dividend increases and Skyrizi/Rinvoq successfully replacing Humira revenue post-biosimilar erosion
value AbbVie's diversified revenue across immunology (Skyrizi/Rinvoq), oncology (Imbruvica), and aesthetics (Botox) reducing single-drug pipeline dependence
want reliable pharmaceutical income from a company with demonstrated ability to manage major drug patent losses while maintaining dividend growth
are comfortable with Humira biosimilar ongoing revenue erosion, Rinvoq JAK inhibitor prescribing limitations, and need for continued pipeline development beyond current portfolio

LLY may suit investors who:

prefer the highest-growth large pharmaceutical company in decades as tirzepatide addresses obesity — a 650M-person global opportunity that dwarfs any prior drug market
value Eli Lilly's tirzepatide clinical differentiation (dual GIP/GLP-1, superior weight loss) creating sustainable market share vs Novo Nordisk's semaglutide
want transformational pharmaceutical growth multiple justified by GLP-1 market penetration potential as the obesity treatment market matures over the next decade
are comfortable with Lilly's premium valuation reflecting GLP-1 expectations, manufacturing capacity constraints, oral GLP-1 competition risk, and minimal current dividend yield

Performance & AI score

Performance & AI score
Metric	ABBV	LLY
AI scorei	N/A	N/A
AI ranki	N/A	N/A
Latest closei	N/A	N/A
1M returni	N/A	N/A
6M returni	N/A	N/A
1Y returni	N/A	N/A

Valuation & upside potential

Valuation & upside potential
Metric	ABBV	LLY
Market capi	N/A	N/A
Trailing P/Ei	N/A	N/A
Forward P/Ei	N/A	N/A
Price/Salesi	N/A	N/A
EV/Revenuei	N/A	N/A
Analyst targeti	N/A	N/A
Target upsidei	N/A	N/A

Full DCF model for LLY

Growth, profitability & risk

Growth, profitability & risk
Metric	ABBV	LLY
Revenue growthi	N/A	N/A
Earnings growthi	N/A	N/A
EPS growthi	N/A	N/A
FCF margini	N/A	N/A
Operating margini	N/A	N/A
Profit margini	N/A	N/A
ROIC proxyi	N/A	N/A
Return on equityi	N/A	N/A
Dividend yieldi	N/A	N/A
Payout ratioi	N/A	N/A
Dividend growth streaki	N/A	N/A
Betai	N/A	N/A
Debt/equityi	N/A	N/A
Current ratioi	N/A	N/A
Quick ratioi	N/A	N/A

Drawdown & downside risk

Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.

1Y risk snapshot

ABBV max drawdowniN/A

LLY max drawdowniN/A

ABBV max wkly dropiN/A

LLY max wkly dropiN/A

5Y risk snapshot

ABBV max drawdowniN/A

LLY max drawdowniN/A

ABBV max wkly dropiN/A

LLY max wkly dropiN/A

10Y risk snapshot

ABBV max drawdowniN/A

LLY max drawdowniN/A

ABBV max wkly dropiN/A

LLY max wkly dropiN/A

Performance metrics by period

Performance metrics by period
Period	Metric	ABBV	LLY
1Y	Growthi	N/A	N/A
	CAGRi	N/A	N/A
	Volatilityi	N/A	N/A
	Sharpe ratioi	N/A	N/A
	Sortino ratioi	N/A	N/A
	Max drawdowni	N/A	N/A
	Current drawdowni	N/A	N/A
	Avg drawdowni	N/A	N/A
	Ulcer Indexi	N/A	N/A
	Max daily dropi	N/A	N/A
	Max wkly dropi	N/A	N/A
5Y	Growthi	N/A	N/A
	CAGRi	N/A	N/A
	Volatilityi	N/A	N/A
	Sharpe ratioi	N/A	N/A
	Sortino ratioi	N/A	N/A
	Max drawdowni	N/A	N/A
	Current drawdowni	N/A	N/A
	Avg drawdowni	N/A	N/A
	Ulcer Indexi	N/A	N/A
	Max daily dropi	N/A	N/A
	Max wkly dropi	N/A	N/A
10Y	Growthi	N/A	N/A
	CAGRi	N/A	N/A
	Volatilityi	N/A	N/A
	Sharpe ratioi	N/A	N/A
	Sortino ratioi	N/A	N/A
	Max drawdowni	N/A	N/A
	Current drawdowni	N/A	N/A
	Avg drawdowni	N/A	N/A
	Ulcer Indexi	N/A	N/A
	Max daily dropi	N/A	N/A
	Max wkly dropi	N/A	N/A

AI Prediction Signali

Members only

Next 5 trading days

ABBV

+2.8%BUY

LLY

+1.1%HOLD

Next 30 trading days

ABBV

+6.4%BUY

LLY

+3.2%HOLD

Start Free Trial Log in

ML model trained on historical prices · 14-day free trial · No credit card required

Business comparison

Business comparison
Category	ABBV	LLY
Company	AbbVie Inc.	Eli Lilly and Company
Sector	Healthcare	Healthcare
Industry	N/A	N/A
Core business	AbbVie is a biopharmaceutical company known for Humira (adalimumab — the world's best-selling drug for most of its history) for autoimmune diseases, and increasingly for its post-Humira portfolio: Skyrizi (IL-23 inhibitor for psoriasis/IBD) and Rinvoq (JAK inhibitor for RA, atopic dermatitis, and more). AbbVie also has Imbruvica (BTK inhibitor for blood cancers) and botox/aesthetics via Allergan. AbbVie is known as a premier dividend growth company having extended J&J's Dividend Aristocrat streak.	Eli Lilly is a pharmaceutical company experiencing extraordinary growth from its GLP-1 receptor agonist drugs for obesity (Zepbound/tirzepatide) and diabetes (Mounjaro/tirzepatide). Tirzepatide targets both GIP and GLP-1 receptors, producing superior weight loss vs semaglutide (Wegovy/Ozempic). Lilly also has Verzenio (breast cancer), Talvey (multiple myeloma), and a robust Alzheimer's pipeline including donanemab (Kisunla). Lilly is executing a massive manufacturing capacity expansion to meet GLP-1 demand.
Investor focus	Investors track Skyrizi and Rinvoq revenue growth as Humira replacements, Humira biosimilar erosion rate, Allergan aesthetics (Botox) performance, and AbbVie's dividend growth track record.	Investors track Mounjaro/Zepbound quarterly revenue and supply availability, GLP-1 market share vs Novo Nordisk's semaglutide, and manufacturing capacity expansion timeline.

ABBV strengths

Skyrizi and Rinvoq are on track to collectively exceed Humira peak revenues — AbbVie's post-Humira portfolio transition appears more successful than many expected
Allergan acquisition added Botox aesthetics as a resilient premium consumer healthcare business with pricing power and global brand recognition
Exceptional dividend growth history — AbbVie has raised its dividend for 50+ consecutive years (including Abbott Labs years), one of the strongest dividend track records in pharma

LLY strengths

Tirzepatide's dual GIP/GLP-1 mechanism produces superior weight loss (~21% body weight) vs semaglutide (~15%) — clinical differentiation in the largest drug market opportunity in history
Obesity as a disease affects 650M+ people globally — even a small market penetration creates extraordinary revenue scale for Lilly's Zepbound
Verzenio CDK4/6 inhibitor growing strongly in breast cancer, Kisunla Alzheimer's approval provides additional non-obesity growth vectors

Risks to watch — ABBV

Humira biosimilar erosion is ongoing — multiple biosimilars are taking US market share, reducing Humira revenue that once drove 50%+ of AbbVie's total revenue
Rinvoq's JAK inhibitor class has FDA black box warning requirements that limit prescribing vs biologics — competing with Dupixent and other biologics
AbbVie's pipeline beyond Skyrizi/Rinvoq is less visible — investors need to see new pipeline assets to gain confidence in post-Skyrizi/Rinvoq long-term growth

Risks to watch — LLY

Lilly's valuation reflects enormous GLP-1 expectations — manufacturing capacity constraints and competition from Novo Nordisk and new entrants (oral GLP-1s, amgen, etc.) could disappoint
Manufacturing scale-up for tirzepatide is a multi-year constraint — supply shortages limit revenue relative to demand
Oral GLP-1 competition (semaglutide oral, orforglipron) could disrupt injectable GLP-1 demand if oral efficacy approaches injectable performance

Frequently asked questions

AbbVie offers dividend income and immunology stability with a successful Humira succession story; Eli Lilly offers the highest pharmaceutical growth potential in decades through tirzepatide obesity dominance. For pharma income and dividend compounding, AbbVie; for pharmaceutical growth exposure to the GLP-1 obesity market opportunity, Eli Lilly. They serve fundamentally different investor needs.

Free public comparison

Want deeper AI forecasts?

This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.

Start Free Trial Read Investing Guides

In-Depth Reports

Full valuation workup with AI Score, Monte Carlo forecast, and bull/bear case — free preview, premium data from $3.99.

LLY Report

Related comparisons